Related Experiment Videos
Rheumatic diseases--clinical experience with piroxicam-beta-cyclodextrin
1Istituto Ortopedico Toscano, Florence, Italy.
European Journal of Rheumatology and Inflammation
|January 1, 1993
Summary
Piroxicam-beta-cyclodextrin (PBC) offers improved gastrointestinal safety for treating rheumatoid arthritis and osteoarthritis compared to piroxicam. This enhanced formulation maintains efficacy while reducing side effects in long-term rheumatic disease management.
Area of Science:
- Rheumatology
- Pharmacology
- Gastroenterology
Background:
- Osteoarthritis and rheumatoid arthritis are chronic inflammatory conditions requiring long-term pain and inflammation management.
- Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) used for rheumatic diseases, but its use can be limited by gastrointestinal side effects.
- Piroxicam-beta-cyclodextrin (PBC) is a modified formulation of piroxicam aimed at improving its tolerability.
Purpose of the Study:
- To review the clinical relevance and efficacy of piroxicam-beta-cyclodextrin (PBC) in long-term treatment of osteoarthritis and rheumatoid arthritis.
- To compare the safety and efficacy of PBC with piroxicam and tenoxicam in patients with rheumatic diseases.
Main Methods:
- A double-blind, randomized, controlled study involving 225 patients (100 with rheumatoid arthritis, 125 with osteoarthritis) compared PBC and piroxicam over 12 weeks.
- A separate study randomly assigned 30 patients with chronic osteoarthritis to receive PBC or tenoxicam daily for 8 weeks.
- Efficacy was assessed via pain intensity, inflammation severity, and functional impairment. Endoscopic evaluation assessed gastrointestinal mucosal lesions.
Main Results:
- Piroxicam demonstrated good analgesic effects, with no significant difference between PBC and piroxicam formulations.
- PBC showed better tolerance and a lower incidence and severity of side effects, primarily gastrointestinal, compared to piroxicam.
- Both PBC and tenoxicam effectively reduced pain, inflammation, and functional limitations in osteoarthritis patients, with PBC associated with less severe mucosal lesions.
Conclusions:
- PBC improves the safety profile of piroxicam for long-term treatment of rheumatic diseases without compromising efficacy.
- Microencapsulation of piroxicam as PBC provides a new drug with superior tolerability compared to piroxicam, effectively managing symptoms of primary rheumatic diseases.